Effectiveness of polyhexamethylene biguanide dressings vs. platelet-rich plasma in diabetic foot ulcer: a pilot study of case series

Authors

  • Roerto Martínez-Mejorada Departament of Plastic, Aesthetic and Reconstructive Surgery, University Hospital, Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, N. L., México
  • Jorge A. Rojas-Ortiz Department of Plastic Surgery, General Hospital, Dr. Ruben Leñero, México city, Mexico https://orcid.org/0000-0002-9541-0787
  • Sandra C. López-Romero Department of General Surgery, General Hospital of México, México
  • Ximena C. Vázquez-Guerra Departament of Plastic, Aesthetic and Reconstructive Surgery, University Hospital, Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, N. L., México https://orcid.org/0009-0001-8327-217X
  • Gabriel Garcia Gonzalez Departament of Plastic, Aesthetic and Reconstructive Surgery, University Hospital, Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, N. L., México https://orcid.org/0000-0003-2139-6086

DOI:

https://doi.org/10.18203/2320-6012.ijrms20240540

Keywords:

Polyhexamethylene biguanide dressings, Platelet-rich plasma, Diabetic foot ulcer

Abstract

Diverse treatments, including polyhexamethylene biguanide dressings, have been explored for managing diabetic foot ulcers. Platelet-rich plasma, known for its potential in chronic wound healing, has demonstrated efficacy both in vivo and in vitro, with possible intralesional or topical application. However, research on the production costs of PRP is scarce. This study compares the effectiveness and financial implications of polyhexamethylene biguanide dressings versus Platelet-rich Plasma in the treatment of diabetic foot ulcers. Conducted at the General Hospital of Mexico from July to August 2019, this case series involved 8 patients, split equally between the two treatment groups. Weekly assessments showed consistent reductions in wound size in both groups. By the fourth week, 75% of patients achieved clinical healing. The PHMB group demonstrated a 75.13% reduction in wound size, compared to a 37.38% reduction in the PRP group. However, due to the small sample size, no statistical significance was found between wound size, healing time, and dressing type. This report suggests no clear relationship between treatment, healing duration, and wound diameter. Additionally, PRP did not show a clear financial advantage over PHMB dressings. Randomized control trials with sufficient sample sizes are required to demonstrate overall advantage for each therapy choice.

Metrics

Metrics Loading ...

References

Jeffcoate WJ, Vileikyte L, Boyko EJ, Armstrong DG, Boulton AJM. Current Challenges and Opportunities in the Prevention and Management of Diabetic Foot Ulcers. Diabetes Care. 2018;41(4):645-52.

Elraiyah T, Domecq JP, Prutsky G, Tsapas A, Nabhan M, Frykberg RG, et al. A systematic review and meta-analysis of débridement methods for chronic diabetic foot ulcers. J Vasc Surg. 2016;63(2):37S-45.

Iversen MM, Tell GS, Riise T, Hanestad BR, Østbye T, Graue M, Midthjell K. History of foot ulcer increases mortality among individuals with diabetes: ten-year follow-up of the Nord-Trøndelag Health Study, Norway. Diabetes Care. 2009;32(12):2193-9.

Ibrahim A. IDF Clinical Practice Recommendation on the Diabetic Foot: A guide for healthcare professionals. Diabetes Res Clin Pract. 2017;127:285-7.

Rojas-Ortiz JA, López RCP, Morales HLV, Ordoñez RH, Mejorada RM, González GG. Application of the laboratory riskindicator for necrotizing fasciitis score for patientswith hand infection in Mexican population. Int J Res Med Sci. 2023;11:1477-82.

Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2): 217-28.

American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. American Diabetes Association. Diabetes Care. 1999; 22(8):1354-60. 7.

Armstrong DG, Lipsky BA. Diabetic foot infections: stepwise medical and surgical management. Int Wound J. 2004;1(2):123-32.

Navarro-Flores E, Cauli O. Quality of Life in Individuals with Diabetic Foot Syndrome. Endocr Metab Immune Disord Drug Targets. 2020;20(9): 1365-72.

Amin N, Doupis J. Diabetic foot disease: From the evaluation of the "foot at risk" to the novel diabetic ulcer treatment modalities. World J Diabetes. 2016; 7(7):153-64.

Guiomar AJ, Urbano AM. Polyhexanide-Releasing Membranes for Antimicrobial Wound Dressings: A Critical Review. Membranes. 2022;12(12):1281.

Günther F, Blessing B, Dapunt U, Mischnik A, Mutters NT. Ability of chlorhexidine, octenidine, polyhexanide and chloroxylenol to inhibit metabolism of biofilm-forming clinical multidrug-resistant organisms. J Infect Prev. 2021;22(1):12-18.

Hübner NO, Matthes R, Koban I, Rändler C, Müller G, Bender C, et al. Efficacy of chlorhexidine, polihexanide and tissue-tolerable plasma against Pseudomonas aeruginosa biofilms grown on polystyrene and silicone materials. Skin Pharmacol Physiol. 2010;23:28-34.

Sibbald RG, Coutts P, Woo KY. Reduction of bacterial burden and pain in chronic wounds using a new polyhexamethylene biguanide antimicrobial foam dressing-clinical trial results. Adv Skin Wound Care. 2011;24(2):78-84. 14.

Eberlein T, Haemmerle G, Signer M, Gruber Moesenbacher U, Traber J, Mittlboeck M, et al. Comparison of PHMB-containing dressing and silver dressings in patients with critically colonised or locally infected wounds. J Wound Care. 2012;21(1): 12.

To E, Dyck R, Gerber S, Kadavil S, Woo KY. The Effectiveness of Topical Polyhexamethylene Biguanide (PHMB) Agents for the Treatment of Chronic Wounds: A Systematic Review. Surg Technol Int. 2016;29:45-51.

Mancini S, Cuomo R, Poggialini M, D'Aniello C, Botta G. Autolytic debridement and management of bacterial load with an occlusive hydroactive deressing impregnated with polyhexamethylene biguanide. Acta Biomed. 2018;88(4):409-13.

Hurlow J. The benefits of using polyhexamethylene biguanide in wound care. Br J Community Nurs. 2017;22:S16-7.

Meznerics FA, Fehérvári P, Dembrovszky F, Kovács KD, Kemény LV, Csupor D, et al. Platelet-Rich Plasma in Chronic Wound Management: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Clin Med. 2022;11(24): 7532.

McAleer JP, Sharma S, Kaplan EM, Persich G. Use of autologous platelet concentrate in a nonhealing lower extremity wound. Adv Skin Wound Care. 2006; 19(7):354-63.

Salemi S, Rinaldi C, Manna F, Guarneri GF, Parodi PC. Reconstruction of lower leg skin ulcer with autologous adipose tissue and platelet-rich plasma. J Plast Reconstr Aesthet Surg. 2008;61(12):1565-7.

Dougherty EJ. An evidence-based model comparing the cost-effectiveness of platelet-rich plasma gel to alternative therapies for patients with nonhealing diabetic foot ulcers. Adv Skin Wound Care. 2008; 21(12):568-75.

Ribeiro APL, Oliveira BGRB. Production cost of autologous platelet rich plasma gel. Rev Lat Am Enfermagem. 2019;27:e3221.

Lavery LA, Armstrong DG, Harkless LB. Classification of diabetic foot wounds. J Foot Ankle Surg. 1996;35(6):528-31.

Ahmed M, Reffat SA, Hassan A, Eskander F. Platelet-Rich Plasma for the Treatment of Clean Diabetic Foot Ulcers. Ann Vasc Surg. 2017;38:206-11.

Margolis DJ, Gelfand JM, Hoffstad O, Berlin JA. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2003; 26(6):1696-700.

Zehnder T, Blatti M. Faster Than Projected Healing in Chronic Venous and Diabetic Foot Ulcers When Treated with Intact Fish Skin Grafts Compared to Expected Healing Times for Standard of Care: An Outcome-Based Model from a Swiss Hospital. Int J Low Extrem Wounds. 2022.

Margolis DJ, Mitra N, Hoffstad O, Malay DS, Mirza ZK, Lantis JC, et al. Circulating endothelial precursor cells are associated with a healed diabetic foot ulcer evaluated in a prospective cohort study. Wound Repair Regen. 2023;31(1):128-34.

Verdú-Soriano J, de Cristino-Espinar M, Luna-Morales S, Dios-Guerra C, Caballero-Villarraso J, Moreno-Moreno P, et al. Superiority of a Novel Multifunctional Amorphous Hydrogel Containing Olea europaea Leaf Extract (EHO-85) for the Treatment of Skin Ulcers: A Randomized, Active-Controlled Clinical Trial. J Clin Med. 2022;11(5): 1260.

Jayalakshmi M. Estimation of percent wound area reduction over a period of four weeks among diabetic foot ulcers. Int J Res Pharma Sci. 2020;11:4503-10.

Ribeiro APL, Oliveira BGRB. Production cost of autologous platelet rich plasma gel. Rev Lat Am Enfermagem. 2019;27:e3221.

Strijbos D, Schoon EJ, Curvers W, Friederich P, Flink HJ, Stronkhorst A, et al. Antibacterial gauzes are effective in preventing infections after percutaneous endoscopic gastrostomy placement: a retrospective analysis. Eur J Gastroenterol Hepatol. 2016;28(3): 297-304.

Downloads

Published

2024-02-28

How to Cite

Martínez-Mejorada, R., Rojas-Ortiz, J. A., López-Romero, S. C., Vázquez-Guerra, X. C., & Gonzalez, G. G. (2024). Effectiveness of polyhexamethylene biguanide dressings vs. platelet-rich plasma in diabetic foot ulcer: a pilot study of case series. International Journal of Research in Medical Sciences, 12(3), 923–927. https://doi.org/10.18203/2320-6012.ijrms20240540

Issue

Section

Case Series